19 December 2024 : Clinical Research
Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes
Wei Li ACDE 1*, Yi Li BEF 2, Chen Liu DE 1, Jinghao Yuan BCDE 1, Weize Fan CDEF 1, Qing Miao BEF 1, Xinshun Gu ADE 1DOI: 10.12659/MSM.945457
Med Sci Monit 2024; 30:e945457
Table 5 Adverse events of both groups.
| Outcomes | Aspirin group (n=84) | Aspirin + rivaroxaban group (n=84) | P value |
|---|---|---|---|
| Allergy | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Gastrointestinal bleeding | 0 (0.0%) | 1 (1.19%) | 1.000 |
| Intracranial hemorrhage | 1 (1.19%) | 1 (1.19%) | 1.000 |
| Urinary bleeding | 0 (0.0%)0 | 0 (0.0%) | 1.000 |
| Meets the 3–5 levels of the BARC bleeding grading criteria | 1 (1.19%) | 1 (1.19%) | 1.000 |
| Meets the 1–2 levels of the BARC bleeding grading criteria | 1 (1.19%) | 2 (2.38%) | 1.000 |
| Total | 2 (2.38%) | 3 (3.57%) | 0.650 |
| BARC – bleeding academic research consortium. | |||